Identification and Characterization of Fenofibrate-Induced Liver Injury

Jawad Ahmad, Joseph A. Odin, Paul H. Hayashi, Naga Chalasani, Robert J. Fontana, Huiman Barnhart, Elizabeth T. Cirulli, David E. Kleiner, Jay H. Hoofnagle

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Fenofibrate is a commonly used hypolipidemic associated with rare instances of hepatotoxicity, and routine liver biochemistry monitoring is recommended. Aims: The aim of this study is to describe the presenting clinical features, liver histopathology, and outcomes of 7 cases of acute liver injury associated with fenofibrate. Methods: All cases of definite, very likely, and probable drug-induced liver injury (DILI) attributed to fenofibrate enrolled in the DILI Network study between 2004 and 2015 were reviewed. Results: Among 1229 patients with confirmed DILI, 7 cases (0.6%) were attributed to fenofibrate. The median age was 43 (range 37–61) years, and latency to onset was short (5–8 weeks) in 4 patients but more prolonged (18–56 weeks) in the rest. Laboratory results at presentation showed hepatocellular, mixed, and cholestatic injury, but 6 cases presented with jaundice. No patient had undergone routine monitoring. Four patients required hospitalization and 2 in whom drug discontinuation was delayed had a severe outcome, 1 undergoing liver transplantation, and 1 developing chronic injury and death. Liver biopsy was available in 4 patients and showed diverse injury patterns. Genetic studies showed the presence of the rare HLA-A*33:01 in 3 patients (43 vs. 1% in control populations). The causality scores were highly likely in 5 and probable in 2. Conclusions: Liver injury after fenofibrate exposure occurs with variable latency, enzyme elevation, and histology. Although most cases are self-limited, severe injury and mortality can occur, particularly if drug withdrawal is delayed. Jaundice or abnormal laboratory tests during fenofibrate therapy should trigger prompt discontinuation.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalDigestive Diseases and Sciences
DOIs
StateAccepted/In press - Nov 8 2017
Externally publishedYes

Fingerprint

Fenofibrate
Chemical and Drug Induced Liver Injury
Liver
Wounds and Injuries
Jaundice
HLA-A Antigens
Causality
Pharmaceutical Preparations
Biochemistry
Liver Transplantation
Histology
Hospitalization
Biopsy
Mortality
Enzymes
Population

Keywords

  • Fenofibrate
  • Hepatotoxicity
  • Liver injury tests

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology

Cite this

Ahmad, J., Odin, J. A., Hayashi, P. H., Chalasani, N., Fontana, R. J., Barnhart, H., ... Hoofnagle, J. H. (Accepted/In press). Identification and Characterization of Fenofibrate-Induced Liver Injury. Digestive Diseases and Sciences, 1-9. https://doi.org/10.1007/s10620-017-4812-7

Identification and Characterization of Fenofibrate-Induced Liver Injury. / Ahmad, Jawad; Odin, Joseph A.; Hayashi, Paul H.; Chalasani, Naga; Fontana, Robert J.; Barnhart, Huiman; Cirulli, Elizabeth T.; Kleiner, David E.; Hoofnagle, Jay H.

In: Digestive Diseases and Sciences, 08.11.2017, p. 1-9.

Research output: Contribution to journalArticle

Ahmad, J, Odin, JA, Hayashi, PH, Chalasani, N, Fontana, RJ, Barnhart, H, Cirulli, ET, Kleiner, DE & Hoofnagle, JH 2017, 'Identification and Characterization of Fenofibrate-Induced Liver Injury', Digestive Diseases and Sciences, pp. 1-9. https://doi.org/10.1007/s10620-017-4812-7
Ahmad, Jawad ; Odin, Joseph A. ; Hayashi, Paul H. ; Chalasani, Naga ; Fontana, Robert J. ; Barnhart, Huiman ; Cirulli, Elizabeth T. ; Kleiner, David E. ; Hoofnagle, Jay H. / Identification and Characterization of Fenofibrate-Induced Liver Injury. In: Digestive Diseases and Sciences. 2017 ; pp. 1-9.
@article{91534949f5ea4c5c842802cc102fcfc6,
title = "Identification and Characterization of Fenofibrate-Induced Liver Injury",
abstract = "Background: Fenofibrate is a commonly used hypolipidemic associated with rare instances of hepatotoxicity, and routine liver biochemistry monitoring is recommended. Aims: The aim of this study is to describe the presenting clinical features, liver histopathology, and outcomes of 7 cases of acute liver injury associated with fenofibrate. Methods: All cases of definite, very likely, and probable drug-induced liver injury (DILI) attributed to fenofibrate enrolled in the DILI Network study between 2004 and 2015 were reviewed. Results: Among 1229 patients with confirmed DILI, 7 cases (0.6{\%}) were attributed to fenofibrate. The median age was 43 (range 37–61) years, and latency to onset was short (5–8 weeks) in 4 patients but more prolonged (18–56 weeks) in the rest. Laboratory results at presentation showed hepatocellular, mixed, and cholestatic injury, but 6 cases presented with jaundice. No patient had undergone routine monitoring. Four patients required hospitalization and 2 in whom drug discontinuation was delayed had a severe outcome, 1 undergoing liver transplantation, and 1 developing chronic injury and death. Liver biopsy was available in 4 patients and showed diverse injury patterns. Genetic studies showed the presence of the rare HLA-A*33:01 in 3 patients (43 vs. 1{\%} in control populations). The causality scores were highly likely in 5 and probable in 2. Conclusions: Liver injury after fenofibrate exposure occurs with variable latency, enzyme elevation, and histology. Although most cases are self-limited, severe injury and mortality can occur, particularly if drug withdrawal is delayed. Jaundice or abnormal laboratory tests during fenofibrate therapy should trigger prompt discontinuation.",
keywords = "Fenofibrate, Hepatotoxicity, Liver injury tests",
author = "Jawad Ahmad and Odin, {Joseph A.} and Hayashi, {Paul H.} and Naga Chalasani and Fontana, {Robert J.} and Huiman Barnhart and Cirulli, {Elizabeth T.} and Kleiner, {David E.} and Hoofnagle, {Jay H.}",
year = "2017",
month = "11",
day = "8",
doi = "10.1007/s10620-017-4812-7",
language = "English (US)",
pages = "1--9",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",

}

TY - JOUR

T1 - Identification and Characterization of Fenofibrate-Induced Liver Injury

AU - Ahmad, Jawad

AU - Odin, Joseph A.

AU - Hayashi, Paul H.

AU - Chalasani, Naga

AU - Fontana, Robert J.

AU - Barnhart, Huiman

AU - Cirulli, Elizabeth T.

AU - Kleiner, David E.

AU - Hoofnagle, Jay H.

PY - 2017/11/8

Y1 - 2017/11/8

N2 - Background: Fenofibrate is a commonly used hypolipidemic associated with rare instances of hepatotoxicity, and routine liver biochemistry monitoring is recommended. Aims: The aim of this study is to describe the presenting clinical features, liver histopathology, and outcomes of 7 cases of acute liver injury associated with fenofibrate. Methods: All cases of definite, very likely, and probable drug-induced liver injury (DILI) attributed to fenofibrate enrolled in the DILI Network study between 2004 and 2015 were reviewed. Results: Among 1229 patients with confirmed DILI, 7 cases (0.6%) were attributed to fenofibrate. The median age was 43 (range 37–61) years, and latency to onset was short (5–8 weeks) in 4 patients but more prolonged (18–56 weeks) in the rest. Laboratory results at presentation showed hepatocellular, mixed, and cholestatic injury, but 6 cases presented with jaundice. No patient had undergone routine monitoring. Four patients required hospitalization and 2 in whom drug discontinuation was delayed had a severe outcome, 1 undergoing liver transplantation, and 1 developing chronic injury and death. Liver biopsy was available in 4 patients and showed diverse injury patterns. Genetic studies showed the presence of the rare HLA-A*33:01 in 3 patients (43 vs. 1% in control populations). The causality scores were highly likely in 5 and probable in 2. Conclusions: Liver injury after fenofibrate exposure occurs with variable latency, enzyme elevation, and histology. Although most cases are self-limited, severe injury and mortality can occur, particularly if drug withdrawal is delayed. Jaundice or abnormal laboratory tests during fenofibrate therapy should trigger prompt discontinuation.

AB - Background: Fenofibrate is a commonly used hypolipidemic associated with rare instances of hepatotoxicity, and routine liver biochemistry monitoring is recommended. Aims: The aim of this study is to describe the presenting clinical features, liver histopathology, and outcomes of 7 cases of acute liver injury associated with fenofibrate. Methods: All cases of definite, very likely, and probable drug-induced liver injury (DILI) attributed to fenofibrate enrolled in the DILI Network study between 2004 and 2015 were reviewed. Results: Among 1229 patients with confirmed DILI, 7 cases (0.6%) were attributed to fenofibrate. The median age was 43 (range 37–61) years, and latency to onset was short (5–8 weeks) in 4 patients but more prolonged (18–56 weeks) in the rest. Laboratory results at presentation showed hepatocellular, mixed, and cholestatic injury, but 6 cases presented with jaundice. No patient had undergone routine monitoring. Four patients required hospitalization and 2 in whom drug discontinuation was delayed had a severe outcome, 1 undergoing liver transplantation, and 1 developing chronic injury and death. Liver biopsy was available in 4 patients and showed diverse injury patterns. Genetic studies showed the presence of the rare HLA-A*33:01 in 3 patients (43 vs. 1% in control populations). The causality scores were highly likely in 5 and probable in 2. Conclusions: Liver injury after fenofibrate exposure occurs with variable latency, enzyme elevation, and histology. Although most cases are self-limited, severe injury and mortality can occur, particularly if drug withdrawal is delayed. Jaundice or abnormal laboratory tests during fenofibrate therapy should trigger prompt discontinuation.

KW - Fenofibrate

KW - Hepatotoxicity

KW - Liver injury tests

UR - http://www.scopus.com/inward/record.url?scp=85033409130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033409130&partnerID=8YFLogxK

U2 - 10.1007/s10620-017-4812-7

DO - 10.1007/s10620-017-4812-7

M3 - Article

C2 - 29119413

AN - SCOPUS:85033409130

SP - 1

EP - 9

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

ER -